Vor Biopharma Inc. (NASDAQ:VOR) Receives $42.25 Consensus Price Target from Brokerages

Vor Biopharma Inc. (NASDAQ:VOR) has received an average rating of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $42.25.

Several research analysts recently weighed in on VOR shares. Wedbush boosted their target price on shares of Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Wells Fargo & Company started coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price for the company. Wall Street Zen downgraded shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Vor Biopharma in a research note on Monday, May 18th.

Vor Biopharma Trading Down 2.7%

Vor Biopharma stock opened at $14.57 on Tuesday. Vor Biopharma has a 52 week low of $3.63 and a 52 week high of $65.80. The firm’s 50-day simple moving average is $15.20 and its 200 day simple moving average is $13.64.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings data on Monday, March 30th. The company reported $307.61 EPS for the quarter. As a group, sell-side analysts predict that Vor Biopharma will post -2.51 EPS for the current fiscal year.

Insider Activity at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 589,257 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $16.59, for a total transaction of $9,775,773.63. Following the completion of the transaction, the director owned 4,555,741 shares of the company’s stock, valued at $75,579,743.19. This represents a 11.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders have sold 3,002,903 shares of company stock worth $49,412,176. Corporate insiders own 0.45% of the company’s stock.

Institutional Trading of Vor Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. acquired a new stake in Vor Biopharma during the 4th quarter worth approximately $36,000. Goldman Sachs Group Inc. increased its position in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new stake in Vor Biopharma during the 2nd quarter worth approximately $66,000. Chung Wu Investment Group LLC acquired a new stake in Vor Biopharma during the 4th quarter worth approximately $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new stake in Vor Biopharma during the 4th quarter worth approximately $134,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).